nach oben

Erschienen in:

01.07.2013 | Original Article

ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy

verfasst von: Sara De Dosso, Elena Zanellato, Martina Nucifora, Renzo Boldorini, Angelica Sonzogni, Roberto Biffi, Nicola Fazio, Eraldo Bucci, Ottavio Beretta, Stefano Crippa, Piercarlo Saletti, Milo Frattini

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Adjuvant chemotherapy is gaining an increasing role in resectable gastric cancer. Customizing chemotherapy on the basis of chemosensitivity may improve outcome, and putative predictive molecular markers have been mostly evaluated in Asian patients. We profiled key DNA and damage signaling factors and correlated them with outcome, in a European cohort.

Methods

Formalin-fixed tumor samples obtained from surgical specimens of patients treated with adjuvant cisplatin-based chemotherapy for gastric cancer were analyzed. Immunohistochemistry (IHC) was performed to analyze excision repair cross-complementing gene 1 (ERCC1) and thymidylate synthase (TS) expression, and p53 mutations were detected with direct sequencing.

Results

Among the 68 patient recruited, the median age was 69 (range 30–74), and UICC stage was III in 44 patients (65 %). With a median follow-up of 40.5 months, disease-free and overall survival were 18.0 (95 % CI 13.4–22.76) and 56 months (95 % CI 44.87–67.13), respectively. ERCC1 score was 0 in 14 out 67 (21 %) cases, 1 in 19 (28 %), 2 in 20 (30 %) and 3 in 14 cases (21 %). Longer overall survival (p = 0.04) was found in patients categorized as ERCC1 negative by IHC according to median score. TS score was 0 in 16 out 67 (24 %) cases, 1 in 27 (40 %), 2 in 16 (24 %) and 3 in 8 cases (12 %). Mutations of p53 were found in 21 out 66 (32 %) cases. Neither TS nor p53 were found to correlate with outcome.

Conclusion

Excision repair cross-complementing gene 1 by IHC might predict patients more likely to benefit from adjuvant cisplatin-based chemotherapy in curatively resected gastric cancer. In patients exhibiting ERCC1 positive tumors, alternative regimens should be evaluated.

Songun I, Putter H, Kranenbarg EM et al (2010) Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 11:439–449PubMedCrossRef

Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20PubMedCrossRef

Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN et al (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725–730PubMedCrossRef

Macdonald J, Smalley S, Haller D, et al (2009) Chemoradiation of resected gastric cancer: a 10-year follow-up of the phase III trial INT0116 (SWOG 9008). J Clin Oncol 27(15 suppl), abstr 4515

Okines AF, Cunningham D (2010) Multimodality treatment for localized gastro-oesophageal cancer. Ann Oncol 21(Suppl 7):vii286–vii293PubMedCrossRef

Hermans J, Bonenkamp JJ, Boon MC et al (1993) Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 11:1441–1447PubMed

Earle CC, Maroun JA (1999) Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomized trials. Eur J Cancer 35:1059–1064PubMedCrossRef

Mari E, Floriani I, Tinassi A, Buda A, Belfiglio M, Valentini M et al (2000) Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomized trials. Ann Oncol 11:837–843PubMedCrossRef

Panzini I, Gianni L, Fattori PP et al (2002) Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori 88:21–27PubMed

10.

Paoletti X, Oba K, Burzykowski T et al (2010) Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group. JAMA 303:1729–1737PubMedCrossRef

11.

Sakuramoto S, Sasako M, Yamaguchi T et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810–1820PubMedCrossRef

12.

Sasako M, Sakuramoto S, Katai H et al (2011) Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 29:4387–4393PubMedCrossRef

13.

Bang YJ, Kim YW, Yang HK et al (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379:315–321PubMedCrossRef

14.

Metzger R, Leichman CG, Danenberg KD et al (1998) ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16:309–316PubMed

15.

Matsubara J, Nishina T, Yamada Y et al (2008) Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br J Cancer 98:832–839PubMedCrossRef

16.

Yeh KH, Shun CT, Chen CL et al (1998) High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer 82:1626–1631PubMedCrossRef

17.

Hua D, Huang ZH, Mao Y et al (2007) Thymidylate synthase and thymidine phosphorylase gene expression as predictive parameters for the efficacy of 5-fluorouracil-based adjuvant chemotherapy for gastric cancer. World J Gastroenterol 13:5030–5034PubMed

18.

Choi J, Lim H, Nam DK et al (2001) Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. Br J Cancer 84:186–192PubMedCrossRef

19.

Lenz HJ, Leichman CG, Danenberg KD et al (1996) Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 14:176–182PubMed

20.

Chin KV, Ueda K, Pastan I et al (1992) Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255:459–462PubMedCrossRef

21.

Lowe SW, Ruley HE, Jacks T et al (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957–967PubMedCrossRef

22.

Findlay M, Cunningham D, Norman A et al (1994) A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 5:609–616PubMed

23.

van Krieken JH, Jung A, Kirchner T et al (2008) KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 453:417–431PubMedCrossRef

24.

Olaussen KA, Dunant A, Fouret P et al (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983–991PubMedCrossRef

25.

Zucali AP, Giovannetti E, Destro A et al (2011) Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin. Clin Cancer Res 17:2581–2590PubMedCrossRef

26.

Perrone F, Oggionni M, Birindelli S et al (2003) TP53, p14ARF, p16INK4a and H-ras gene molecular analysis in intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses. Int J Cancer 105:196–203PubMedCrossRef

27.

Rosell R, Taron M, Ariza A et al (2004) Molecular predictors of response to chemotherapy in lung cancer. Semin Oncol 31(1 Suppl 1):20–27PubMedCrossRef

28.

Dabholkar M, Bostick-Bruton F, Weber C et al (1992) ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 84:1512–1517PubMedCrossRef

29.

Reed E (2005) ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res 11:6100–6102PubMedCrossRef

30.

Liu Y, Ling Y, Liu B et al (2010) Use of ERCC1 expression in resected specimen to predict survival in both patients with gastric cancer treated with surgery followed by oxaliplatin-based adjuvant chemotherapy and in those receiving surgery alone. Gastrointestinal Cancers Symposium abstr 29

31.

Kim KH, Kwon HC, Oh SY et al (2011) Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy. Biomarkers 16:74–82PubMedCrossRef

32.

Baek SK, Kim SY, Lee JJ et al (2006) Increased ERCC expression correlates with improved outcome of patients treated with cisplatin as an adjuvant therapy for curatively resected gastric cancer. Cancer Res Treat 38:19–24PubMedCrossRef

33.

Bamias A, Karina M, Papakostas P et al (2010) A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer Chemother Pharmacol 65:1009–1021PubMedCrossRef

34.

Kwon HC, Roh MS, Oh SY et al (2007) Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 18:504–509PubMedCrossRef

35.

Wang Z, Chen JQ, Liu JL et al (2012) Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review. BMC Gastroenterol 12:137PubMedCrossRef

36.

37.

Kim JS, Kim MA, Kim TM et al (2009) Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival. Br J Cancer 100:732–738PubMedCrossRef

38.

39.

40.

Chin KV, Ueda K, Pastan I et al (1992) Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255:459–462PubMedCrossRef

41.

Boku N, Chin K, Hosokawa K et al (1998) Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. Clin Cancer Res 4:1469–1474PubMed

42.

Yeh KH, Shun CT, Chen CL et al (1999) Overexpression of p53 is not associated with drug resistance of gastric cancers to 5-fluorouracil-based systemic chemotherapy. Hepatogastroenterology 46:610–615PubMed

43.

Giatromanolaki A, Stathopoulos GP, Koukourakis MI et al (2001) Angiogenesis and apoptosis-related protein (p53, bcl-2, and bax) expression versus response of gastric adenocarcinomas to paclitaxel and carboplatin chemotherapy. Am J Clin Oncol 24:222–226PubMedCrossRef

44.

Kikuyama S, Inada T, Shimizu K et al (2001) p53, bcl-2 and thymidine phosphorylase as predictive markers of chemotherapy in patients with advanced and recurrent gastric cancer. Anticancer Res 21:2149–2153PubMed

45.

Díez M, Medrano MJ, Gutierrez A et al (2000) P53 protein expression in gastric adenocarcinoma. Negative predictor of survival after postoperative adjuvant chemotherapy. Anticancer Res 20:3929–3933PubMed

Titel: ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy
verfasst von: Sara De Dosso
Elena Zanellato
Martina Nucifora
Renzo Boldorini
Angelica Sonzogni
Roberto Biffi
Nicola Fazio
Eraldo Bucci
Ottavio Beretta
Stefano Crippa
Piercarlo Saletti
Milo Frattini
Publikationsdatum: 01.07.2013
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 1/2013
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-013-2181-2

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy